Inflammatory bowel disease (IBD) pharmacotherapy has evolved rapidly, from conventional immunomodulators to biologicals and targeted therapies. However, translating this expanding therapeutic arsenal into better patient care remains challenging. Clinicians must select the right drug, determine the right dose, monitor effectiveness and safety, and maintain affordability and feasibility within routine care.

This presentation provides an overview of a translational research programme in personalised medicine in IBD, illustrating how pharmacological research can be translated into practical tools, treatment strategies and care innovations. By connecting work on thiopurines, biologicals, precision dosing, healthcare innovation and data-driven clinical decision support, the programme demonstrates how clinical pharmacology can support more personalised and sustainable IBD care.

Rather than highlighting a single study, the presentation follows the broader translational pathway from clinical problem to research question, from evidence generation to clinical implementation, and from individual patient optimisation to improvement of care pathways. By sharing this integrated research and implementation approach, the presentation aims to provide an inspiring example of how clinical pharmacology research can contribute directly to more personalised, effective and sustainable patient care.